PT  - JOURNAL ARTICLE
AU  - Carreño, Juan Manuel
AU  - Wagner, Abram L.
AU  - Monahan, Brian
AU  - Floda, Daniel
AU  - Gonzalez-Reiche, Ana S
AU  - Tcheou, Johnstone
AU  - Raskin, Ariel
AU  - Bielak, Dominika
AU  - Singh, Gagandeep
AU  - Morris, Sara
AU  - Fried, Miriam
AU  - Yellin, Temima
AU  - Sullivan, Leeba
AU  - ,
AU  - Sordillo, Emilia Mia
AU  - Gordon, Aubree
AU  - van Bakel, Harm
AU  - Simon, Viviana
AU  - Krammer, Florian
TI  - SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023
AID  - 10.1101/2023.12.18.23300131
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.18.23300131
4099  - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300131.short
4100  - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300131.full
AB  - Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr. Simon is listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARSCoV-2. Dr. Krammer has consulted for Merck, Seqirus, CureVac and Pfizer in the past, and is currently consulting for Pfizer, 3rd Rock Ventures, GSK and Avimex and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory has been collaborating with Pfizer on animal models for SARS-CoV-2.Funding StatementThis effort was supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. This work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051) and by institutional funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol HS 20-00308 was reviewed by the Mount Sinai Health System Institutional Review Board, Icahn School of Medicine at Mount Sinai, and it was exempt from human research as defined by regulations of the Department of Health and Human Services (45 CFR 46. 104).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes